| 0.0001 -0.001 (-85.71%) | 12-22 14:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0 | 1-year : | 0 |
| Resists | First : | 0 | Second : | 0 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0  |
MA(250) : | 0.19 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 45.5 |
| RSI | RSI(14): 59.9 | |||
| 52-week | High : | 1.45 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GNCA ] has closed below upper band by 15.9%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Wed, 25 May 2022
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know. - InvestorPlace
Tue, 24 May 2022
Genocea Closes Shop, Delists From NASDAQ - Yahoo Finance
Tue, 24 May 2022
Genocea Announces Wind Down of Operations and Delisting From NASDAQ - GlobeNewswire
Thu, 28 Apr 2022
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives - GlobeNewswire
Mon, 11 Apr 2022
Implied Volatility Surging for Genocea (GNCA) Stock Options - Yahoo Finance
Tue, 04 Jan 2022
Genocea Biosciences Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 5.411e+007 (%) |
| Held by Institutions | 6.2 (%) |
| Shares Short | 2,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.567e+007 |
| EPS Est Next Qtrly | -0.38 |
| EPS Est This Year | -1.92 |
| EPS Est Next Year | -1.12 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 958.8 % |
| Return on Equity (ttm) | -57.6 % |
| Qtrly Rev. Growth | 1.91e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -328.62 |
| EBITDA (p.s.) | 1.025e+006 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 1.64e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-05-21 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|